2006
DOI: 10.1038/nbt1185
|View full text |Cite
|
Sign up to set email alerts
|

Identification and immunotherapeutic targeting of antigens induced by chemotherapy

Abstract: Cancer cells differ from normal cells in their response to chemotherapy. We exploited this dissimilarity by identifying and targeting tumor-specific, cell-surface proteins whose expression is induced by the chemotherapeutic irinotecan (CPT-11; Camptosar). A cytotoxin-armed antibody reactive with one of these drug-induced surface proteins, the LY6D/E48 antigen, originally identified as the target of a monoclonal antibody reactive with squamous cell carcinomas, caused complete regression of colorectal tumor xeno… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
41
0

Year Published

2006
2006
2020
2020

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 58 publications
(42 citation statements)
references
References 16 publications
1
41
0
Order By: Relevance
“…Blood samples for complete blood counts, chemistries, and coagulation variables were obtained just before the infusion (on days 1, 8, and 15), 48 hours after the infusion (on days 3, 10, and 17), and 1 week after the last infusion (day 22). On days 1, 3,6,8,10,13,15,17,20,22, and 24, an assessment of the clinical status of the patient was done. On day 29, at the end-of-trial visit, all pretreatment studies were repeated, including tumor staging and assessment.…”
Section: Pretreatment and Follow-up Studiesmentioning
confidence: 99%
See 1 more Smart Citation
“…Blood samples for complete blood counts, chemistries, and coagulation variables were obtained just before the infusion (on days 1, 8, and 15), 48 hours after the infusion (on days 3, 10, and 17), and 1 week after the last infusion (day 22). On days 1, 3,6,8,10,13,15,17,20,22, and 24, an assessment of the clinical status of the patient was done. On day 29, at the end-of-trial visit, all pretreatment studies were repeated, including tumor staging and assessment.…”
Section: Pretreatment and Follow-up Studiesmentioning
confidence: 99%
“…Previous efforts of our group focused on the development of radioimmunoconjugates for radioimmunotherapy because head and neck squamous cell carcinoma is relatively radiosensitive. In our selection of a suitable target antigen for head and neck squamous cell carcinoma, the E48 antigen (7,8) and CD44 splice variants containing the v6 domain (CD44v6) seemed to be the most promising thus far.…”
mentioning
confidence: 99%
“…LY6E is a glycosylphosphatidylinositol (GPI)-linked cell-surface protein that is induced by IFNa (3) and chemotherapy (4). LY6E mRNA was found to be overexpressed in colon and kidney cancer suggesting a role in cancer (5).…”
Section: Introductionmentioning
confidence: 99%
“…However, recent reports have shown that several chemotherapeutic drugs altered the local immune state, affecting the response of the tumor to treatment (6)(7)(8)(9). Several commonly used chemotherapeutic agents, including those commonly used for ovarian cancer such as paclitaxel and gemcitabine, induce immunoreactive effects such as promotion of tumor antigen presentation through upregulating the expression of tumor antigens or MHC class I molecules (10,11).…”
Section: Introductionmentioning
confidence: 99%